Shanghai Sanyou Medical Co., Ltd (SHA:688085)
China · Delayed Price · Currency is CNY 20.53
-0.18 (-0.87%)
Mar 9, 2026, 3:00 PM CST
Shanghai Sanyou Medical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 542.79 | 451.7 | 456.91 | 647.8 | 592.95 |
Other Revenue | - | 1.9 | 3.48 | 1.35 | 0.41 |
| 542.79 | 453.6 | 460.39 | 649.15 | 593.36 | |
Revenue Growth (YoY) | 19.66% | -1.48% | -29.08% | 9.40% | 51.98% |
Cost of Revenue | - | 145.95 | 103.81 | 71.39 | 63.61 |
Gross Profit | 542.79 | 307.65 | 356.58 | 577.77 | 529.75 |
Selling, General & Admin | - | 211.71 | 193.48 | 333.64 | 323.13 |
Research & Development | 83.71 | 84.29 | 65.22 | 60.38 | 56.55 |
Other Operating Expenses | 407.27 | 4.46 | 5.07 | 7.68 | 6.49 |
Operating Expenses | 490.99 | 301.5 | 255 | 404.49 | 389.04 |
Operating Income | 51.81 | 6.14 | 101.58 | 173.28 | 140.71 |
Interest Expense | - | -1.17 | -0.27 | -0.2 | -0.16 |
Interest & Investment Income | - | 13.6 | 16.25 | 14.53 | 34.3 |
Currency Exchange Gain (Loss) | - | -0.74 | 0.32 | 0.1 | -0.17 |
Other Non Operating Income (Expenses) | 4.25 | -1.43 | -0.31 | -0.2 | 0.19 |
EBT Excluding Unusual Items | 56.06 | 16.39 | 117.58 | 187.51 | 174.87 |
Impairment of Goodwill | - | -0.07 | - | - | - |
Gain (Loss) on Sale of Investments | - | 4.16 | -6.89 | 36.32 | 27.33 |
Gain (Loss) on Sale of Assets | - | 6.42 | -0.05 | -0.06 | -0.19 |
Asset Writedown | - | -10.13 | - | - | - |
Other Unusual Items | - | 5.13 | 24.22 | 15.78 | 15.33 |
Pretax Income | 56.06 | 21.9 | 134.87 | 239.54 | 217.33 |
Income Tax Expense | -7.23 | 9.79 | 21.23 | 35.99 | 22.18 |
Earnings From Continuing Operations | 63.29 | 12.11 | 113.64 | 203.56 | 195.15 |
Minority Interest in Earnings | - | -0.64 | -18.06 | -12.74 | -8.78 |
Net Income | 63.29 | 11.47 | 95.58 | 190.82 | 186.37 |
Net Income to Common | 63.29 | 11.47 | 95.58 | 190.82 | 186.37 |
Net Income Growth | 451.85% | -88.00% | -49.91% | 2.39% | 57.20% |
Shares Outstanding (Basic) | 333 | 275 | 302 | 297 | 296 |
Shares Outstanding (Diluted) | 333 | 275 | 302 | 297 | 296 |
Shares Change (YoY) | 21.12% | -8.87% | 1.49% | 0.33% | 8.47% |
EPS (Basic) | 0.19 | 0.04 | 0.32 | 0.64 | 0.63 |
EPS (Diluted) | 0.19 | 0.04 | 0.32 | 0.64 | 0.63 |
EPS Growth | 355.63% | -86.83% | -50.65% | 2.05% | 44.92% |
Free Cash Flow | - | -26.47 | 241.5 | 17.78 | 53.26 |
Free Cash Flow Per Share | - | -0.10 | 0.80 | 0.06 | 0.18 |
Dividend Per Share | - | 0.004 | 0.065 | 0.064 | 0.125 |
Dividend Growth | - | -94.62% | 0.93% | -48.64% | 4.67% |
Gross Margin | 100.00% | 67.82% | 77.45% | 89.00% | 89.28% |
Operating Margin | 9.54% | 1.35% | 22.06% | 26.69% | 23.71% |
Profit Margin | 11.66% | 2.53% | 20.76% | 29.39% | 31.41% |
Free Cash Flow Margin | - | -5.84% | 52.45% | 2.74% | 8.98% |
EBITDA | 82.07 | 36.41 | 127.39 | 188.63 | 153.9 |
EBITDA Margin | 15.12% | 8.03% | 27.67% | 29.06% | 25.94% |
D&A For EBITDA | 30.27 | 30.27 | 25.81 | 15.35 | 13.19 |
EBIT | 51.81 | 6.14 | 101.58 | 173.28 | 140.71 |
EBIT Margin | 9.54% | 1.35% | 22.06% | 26.69% | 23.71% |
Effective Tax Rate | - | 44.70% | 15.74% | 15.02% | 10.21% |
Revenue as Reported | - | 453.6 | 460.39 | 649.15 | 593.36 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.